Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 3/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79729 | 1.00 | EPHX1 (0.56) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL79728 | 1.00 | EPHX1 (0.56) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2814002 | 0.98 | EPHX1 (0.54) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL4590113 | 0.98 | EPHX1 (0.54) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL5033051 | 0.88 | SRR (0.49) | EPHX1TAAR1ALPIPKMPTGS1 | |
| SCHEMBL20704751 | 0.88 | SRR (0.49) | EPHX1TAAR1ALPIPKMPTGS1 | |
| SCHEMBL10521797 | 0.85 | EPHX1 (0.45) | EPHX1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL6285380 | 0.83 | LTA4H (0.61) | SLC6A2MAOASLC6A3PTGS1LAP3 | |
| SCHEMBL6285385 | 0.83 | LTA4H (0.61) | SLC6A2MAOASLC6A3PTGS1LAP3 | |
| SCHEMBL3925001 | 0.83 | LTA4H (0.61) | SLC6A2MAOASLC6A3PTGS1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024392-B | Deuterated kynurenine and application thereof in analysis of amino acid configuration in polypeptide | 上海市食品药品检验研究院 | 2022-09-27 | — | — | CN | claimed |
| CN-113024392-A | Deuterated kynurenine and application thereof in analysis of amino acid configuration in polypeptide | 上海市食品药品检验研究院 | 2021-06-25 | — | — | CN | claimed |
| CN-106866792-B | Cyclodecapeptide molecule and application thereof | 中山大学 | 2020-09-04 | — | — | CN | claimed |
| CN-103059106-B | Polymixin derivative and application thereof | NORTHERN ANTIBIOTICS LTD | 2015-01-14 | — | — | CN | claimed |
| CN-103059106-A | Polymixin derivative and application thereof | NOZERN ANTIBIOTIKS OJ | 2013-04-24 | — | — | CN | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | UNIVERSITY OF MANITOBA (CA) | 2010-10-14 | — | — | US | claimed |
| CN-101812105-A | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof | UNIV SHENYANG PHARMACEUTICAL | 2010-08-25 | — | — | CN | claimed |
| EP-2167522-A2 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | University of Manitoba (CA) | 2010-03-31 | — | — | EP | claimed |
| EP-1694348-A4 | INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN 4-RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | claimed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | claimed |
| EP-0077274-A1 | 3-Amino-2-hydroxy-4-phenylbutanoic acid derivatives and pharmaceutical composition containing the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-04-20 | — | — | EP | claimed |
| EP-0018072-B1 | SYNTHETIC PEPTIDES HAVING PITUITARY GROWTH HORMONE RELEASING ACTIVITY | BECKMAN INSTRUMENTS, INC. (US) | 1983-01-26 | — | — | EP | claimed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | claimed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | claimed |
| US-4314936-A | BY MEASUREM,ENT OF FLUORESENCE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1982-02-09 | — | — | US | claimed |
| EP-0035383-A1 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-09 | — | — | EP | claimed |
| EP-0000559-A1 | Pentapeptide-N-alkylamides and their acid addition salts, methods for preparation of these compounds and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-02-07 | — | — | EP | claimed |
| US-4081433-A | D-Nle4 -somatostatin and analogues thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-03-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | EPHX1 3156/4885SLC6A2 1034/4885TAAR1 478/4885 |
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | NRDC, ANPEP, DNPEP | EPHX1 4880/4885SLC6A2 3602/4885TAAR1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.